



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
IN THE APPLICATION OF:

SHAKER A. MOUSA ET. AL.

CASE NO.: CL1723 US NA

APPLICATION NO.: 10/074389

CONFIRMATION NO.: 5572

GROUP ART UNIT: 1643

EXAMINER:

FILED: FEBRUARY 12, 2002

FOR: ANGIOGENESIS-INHIBITORY TRIPEPTIDES, COMPOSITIONS AND THEIR  
METHODS OF USE

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with 37 CFR 1.97 and 1.98, Applicants would like to bring to the attention of the U.S. Patent and Trademark Office information that may be helpful in the examination of the above-identified patent application. All of the information is listed on an attached Form PTO/SB/08. A copy of the information, when required, is attached hereto. All US patent references were disclosed using the ePave system. The references listed on the enclosed PTO/SB/08B are in addition to the US patent references disclosed via ePave.

Enclosed is a Form PTO/SB/17 authorizing the associated fee to be charged to a Deposit Account of **E. I. du Pont de Nemours and Company**.


Respectfully submitted,

**S. NEIL FELTHAM**  
ATTORNEY FOR APPLICANTS  
Registration No.: 36,506  
Telephone: (302) 992-6460  
Facsimile: (302) 992-5374

10/02/2003 EFLORES 00000142 041928 10074389  
01 FC:1806 180.00 DA

Dated: 9/25/03

Enclosures



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

### Complete if Known

Application Number	10/074389
Filing Date	February 12, 2002
First Named Inventor	Shaker A. Mousa Et. Al.
Art Unit	1643
Examiner Name	
Attorney Docket Number	CL1723 US NA

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Mousa, S. A., Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications, Landes Bioscience, Georgetown, TX; Chapter 1, (2000)	<input type="checkbox"/>
		Breier et al., Trends in Cell Biology, 6: 454-456 (1996)	<input type="checkbox"/>
		Folkman, Nature Medicine 1: 27-31 (1995)	<input type="checkbox"/>
		Risau, Nature 386: 671-674 (1997)	<input type="checkbox"/>
		Blood et al., Bioch. Biophys. Acta. 1032:89-118 (1990)	<input type="checkbox"/>
		Folkman et al., Science 235: 442-447 (1987)	<input type="checkbox"/>
		Moses et al., Science 248: 1408-1410 (1990)	<input type="checkbox"/>
		Folkman et al., Cancer Biology 3: 89-96 (1992)	<input type="checkbox"/>
		Han et al. J. Biol. Chem., 272:20395-20401 (1997)	<input type="checkbox"/>
		Shahan et al. Connective Tissue Res. 40: 221-232 (1999)	<input type="checkbox"/>


Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	10/074389
Filing Date	February 12, 2002
First Named Inventor	Shaker A. Mousa Et. Al.
Art Unit	1643
Examiner Name	
Attorney Docket Number	CL1723 US NA

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Shahan et al., Cancer Res., 59: 4584-4590 (1999)	<input type="checkbox"/>
		Shahan et al., J. Biol. Chem. 275: 4796-4802 (2000)	<input type="checkbox"/>
		Pasco et al., Cancer Res. 60: 467-473 (2000)	<input type="checkbox"/>
		Maeshima et al., J. Biol. Chem. 275: 21340-21348 (2000)	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.